` Comparison: PA8 vs ABBV - Alpha Spread

PA8
vs
ABBV

Over the past 12 months, PA8 has significantly outperformed ABBV, delivering a return of +238% compared to the ABBV's 0% drop.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
PA8
ABBV
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

PA8 Intrinsic Value
Not Available
ABBV Intrinsic Value
233.88 USD
Undervaluation 10%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Multiples-Based Value Wall St Target
Paion AG
F:PA8
0.0324 EUR
Abbvie Inc
NYSE:ABBV
209.4 USD
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
PA8, ABBV

PA8
ABBV
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
Paion AG
Revenue
Abbvie Inc
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
PA8, ABBV

PA8
ABBV
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
Paion AG
F:PA8
Abbvie Inc
NYSE:ABBV
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

PA8
94.1%
ABBV
71.6%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

Operating Margin

PA8
4.5%
ABBV
34.2%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

Net Margin

PA8
-1.7%
ABBV
6.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

FCF Margin

PA8
13.1%
ABBV
29.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

ROE

PA8
-8.8%
ABBV
15 221.8%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

ROA

PA8
-1.5%
ABBV
3.1%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

ROIC

PA8
22.2%
ABBV
14%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

ROCE

PA8
5.9%
ABBV
22.4%
LTM 3Y Avg 5Y Avg 10Y Avg
Paion AG
Abbvie Inc

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
PA8, ABBV

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
PA8, ABBV

Loading
PA8
ABBV
Difference
www.alphaspread.com

Performance By Year
PA8, ABBV

Loading
PA8
ABBV
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare PA8 to other stocks
PNEXF
Pharnext SCA
More expensive
vs PA8
EXAS
Exact Sciences Corp
Cheaper
vs PA8
AMGN
Amgen Inc
Cheaper
vs PA8
GILD
Gilead Sciences Inc
Cheaper
vs PA8
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett